KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Capital Employed: 2014-2025

Historic Return on Capital Employed for Xenon Pharmaceuticals (XENE) over the last 10 years, with Sep 2025 value amounting to -0.57%.

  • Xenon Pharmaceuticals' Return on Capital Employed fell 26.00% to -0.57% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.57%, marking a year-over-year decrease of 26.00%. This contributed to the annual value of -0.33% for FY2024, which is 7.00% down from last year.
  • Xenon Pharmaceuticals' Return on Capital Employed amounted to -0.57% in Q3 2025, which was down 20.10% from -0.47% recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Return on Capital Employed registered a high of -0.13% during Q2 2022, and its lowest value of -0.57% during Q3 2025.
  • Over the past 3 years, Xenon Pharmaceuticals' median Return on Capital Employed value was -0.31% (recorded in 2024), while the average stood at -0.34%.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Return on Capital Employed climbed by 12bps in 2022, and later fell by 26bps in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Return on Capital Employed (Quarterly) stood at -0.20% in 2021, then grew by 2bps to -0.17% in 2022, then fell by 10bps to -0.27% in 2023, then dropped by 9bps to -0.36% in 2024, then fell by 26bps to -0.57% in 2025.
  • Its Return on Capital Employed stands at -0.57% for Q3 2025, versus -0.47% for Q2 2025 and -0.40% for Q1 2025.